Full-Time
Confirmed live in the last 24 hours
Develops genomic tests for cancer diagnosis
$109k - $150kAnnually
Senior
San Diego, CA, USA
You match the following Veracyte's candidate preferences
Employers are more likely to interview you if you match these preferences:
Veracyte develops and sells advanced genomic tests for the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples, such as nasal swabs or tissue biopsies, to provide insights into the presence and progression of cancer. This information helps healthcare providers, including hospitals and clinics, make informed treatment decisions for their patients. Veracyte differentiates itself from competitors by focusing on non-invasive testing methods and continuously investing in research to expand its product offerings. The company's goal is to improve cancer diagnosis accuracy, leading to better patient outcomes and more efficient healthcare resource use.
Company Size
501-1,000
Company Stage
IPO
Total Funding
$69.4M
Headquarters
San Francisco, California
Founded
2008
Help us improve and share your feedback! Did you find this helpful?
Performance Bonus
Stock Options
Remote Work Options
Veracyte, Inc. announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.
HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).
That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.
SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ:VCYT), a global cancer diagnostics company, announced today the addition of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.